Clinical Characteristics of Individuals With Schizophrenia and Hallucinogen Persisting Perception Disorder: A Preliminary Investigation

Lev‐Ran, Shaul; Feingold, Daniel L.; Frenkel, Alma; Lerner, Ana Beatriz Coutinho

doi:10.1080/15504263.2014.906155

Cited by 15 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the literature, we found that the majority of HPPD cases have been induced by LSD or phencyclidine (PCP) (14 studies, 294 patients) [ 17 , 19 , 21 , 26 , 35 , 46 , 51 , 52 , 53 , 55 , 56 , 57 , 58 , 59 ].…”

Section: Resultsmentioning

confidence: 99%

“…Recent observations reported a co-occurrence with depressive [ 20 ] and anxiety traits [ 51 ] and severe mental illnesses such as Major Depressive Disorder [ 23 ], Bipolar Disorder [ 23 , 62 ], and Schizophrenia Spectrum Disorders [ 17 , 58 ]. However, HPPD I and HPPD II onsets are not necessarily accompanied by any prominent additional psychiatric disorder, thus representing an independent condition [ 17 , 18 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

et al. 2018

View full text Add to dashboard Cite

Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs. The aims of the present study are to review all the original studies about HPPD in order to evaluate the following: (1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD induction; (3) the clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities; and (5) the available and potential therapeutic strategies. We searched PubMed to identify original studies about psychedelics and Hallucinogen Persisting Perception Disorder (HPPD). Our research yielded a total of 45 papers, which have been analyzed and tabled to provide readers with the most updated and comprehensive literature review about the clinical features and treatment options for HPPD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Lerner et al ( 19 ) reported two case reports with a prior history of LSD intake, who experienced new visual disturbances, not previously appeared during the first LSD intoxication, after totally stopping substance use ( 34 ). A pilot study recruited 26 inpatients affected with schizophrenia and concomitant self-reported past LSD use who presented with HPPD ( n = 12) or without HPPD ( n = 14) ( 35 ). No significant differences in demographic, clinical features, adverse effects, and response to medications have been reported between the two groups.…”

Section: Resultsmentioning

confidence: 99%

“…No significant differences in demographic, clinical features, adverse effects, and response to medications have been reported between the two groups. Furthermore, the authors reported that patients with schizophrenia and concomitant HPPD were able to distinguish HPPD symptoms from hallucinations related to their own psychotic state ( 35 ). A case-control study recruited a cannabis-user who developed HPPD and four healthy controls in order to evaluate the differences in their ophthalmological state ( 36 ).…”

Section: Resultsmentioning

confidence: 99%

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

et al. 2017

View full text Add to dashboard Cite

Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel psychoactive substances (NPS) posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, including cases of HPPD. Symptomatology mainly comprises visual disorders (i.e., geometric pseudo-hallucinations, haloes, flashes of colors/lights, motion-perception deficits, afterimages, micropsia, more acute awareness of floaters, etc.), even though depressive symptoms and thought disorders may be comorbidly present. Although HPPD was first described in 1954, it was just established as a fully syndrome in 2000, with the revised fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). HPPD neural substrates, risk factors, and aetiopathogenesys still largely remain unknown and under investigation, and many questions about its pharmacological targets remain unanswered too. A critical mini review on psychopathological bases, etiological hypothesis, and psychopharmacological approaches toward HPPD, including the association with some novel substances, are provided here, by means of a literature search on PubMed/Medline, Google Scholar, and Scopus databases without time restrictions, by using a specific set of keywords. Pharmacological and clinical issues are considered, and practical psychopharmacological recommendations and clinical guidelines are suggested.

show abstract

“…Finally, the history of non-opioid substance use disorders (e.g., cannabis, cocaine) has also been associated with increased rates of non-medical PO use [36, 37]. Therefore, differences in rates of PO-related mortality between Israel and other developed countries may be also attributed to a generally lower estimated rate of substance use disorders in Israel compared to that in other European countries and the United States [38]. …”

Section: Discussionmentioning

confidence: 99%

Fatal Overdoses of Opioids in Israel 2005–2014

et al. 2017

Self Cite

View full text Add to dashboard Cite

Aims: To explore previously unreported rates and trends in opioid-related mortality in Israel, 2005–2014. Methods: Data was obtained from the national database on causes of death. Drug poisoning deaths were divided into opioid-related deaths and deaths related to other drugs according to International Classification of Diseases (ICD)-10 code of underlying cause, and included drug poisoning of accidental, intentional or undetermined intent. Age-adjusted rates were calculated per 100,000 population. Rate ratios were calculated and a logistic model constructed to compare the risk of opioid-related deaths in both halves of the decade (2006–2009 and 2009–2013) and between various demographic groups. Results: While age-adjusted rates of deaths related to other drugs remained relatively stable, rates of opioid-related deaths significantly decreased during this period across all groups. During the study period, the number of opioid-related deaths in Israel declined from 1.3 to 0.3 per 100,000. Opioid-related deaths were more common among men, young adults and immigrants from the Former Soviet Union. Conclusions: Rates of opioid-related deaths in Israel were low compared to those reported in the United States and United Kingdom. In addition, the decline in opioid-related deaths in Israel is contrary to trends observed in the United States and United Kingdom. Factors that may contribute to these differences are discussed.

show abstract

Clinical Characteristics of Individuals With Schizophrenia and Hallucinogen Persisting Perception Disorder: A Preliminary Investigation

Abstract: Very little is known about the co-occurrence of schizophrenia and HPPD or the associated clinical implications. Further research is needed to understand the clinical impact of this comorbidity.

Cited by 15 publications

References 13 publications

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

Fatal Overdoses of Opioids in Israel 2005–2014

Contact Info

Product

Resources

About